Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of nilotinib丨cas 641571-10-0 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
Specifications of Nilotinib丨CAS 641571-10-0
|
Appearance |
Off-white to pale yellow powder |
|
Identification |
The main peak of the test solution conform to that of the reference solution |
|
Purity (HPLC) |
99% min |
|
Single impurity |
0.1% max |
|
Water |
0.5% max |
|
Residue on ignition |
0.1% max |
|
Heavy metal |
20 ppm max |
|
Residual solvents - MeOH |
3000 ppm max |
|
Residual solvents - EtOH |
5000 ppm max |
|
Assay |
98.5% - 101.5% |
Transport Information of Nilotinib丨CAS 641571-10-0
|
Parameter |
Specification |
|
UN Number |
|
|
Class |
|
|
Packing Group |
|
|
H.S. Code |
2921499090305 |
|
Stability & Reactivity |
The product is chemically stable under standard ambient conditions. |
|
Storage |
Tightly closed. Dry. 2-8degC |
|
Condition to Avoid |
|
|
Package |
Manufacturing Information of Nilotinib丨CAS 641571-10-0
|
Parameter |
Specification |
|
Capacity |
100kg/month |
|
Frequency |
|
|
Main Export Countries |
|
|
Capacity/Batch |
|
|
Experience |
Production since 2013 |
|
Stock |
Overview
Nilotinib丨CAS 641571-10-0 is a potent, selective tyrosine kinase inhibitor (TKI) primarily used as an oral anticancer drug. It targets the BCR-ABL fusion protein, which is produced in chronic myeloid leukemia (CML) cells due to a genetic abnormality called the Philadelphia chromosome. Nilotinib works by blocking this abnormal enzyme, thereby inhibiting the growth of cancer cells.
Applications
1. Pharmaceutical Use
Treatment of Chronic Myeloid Leukemia (CML):
Nilotinib is mainly prescribed for patients with Philadelphia chromosome-positive CML, especially in cases resistant or intolerant to prior treatment like imatinib.
Other Cancers (Investigational):
Studied for effectiveness in other malignancies involving tyrosine kinases.
2. Research Tool
Used in cancer biology and pharmacology research to study tyrosine kinase signaling pathways.
Employed in drug development to design new TKIs or combination therapies.
Benefits
✅ High Potency and Selectivity
More potent than earlier TKIs like imatinib, allowing better control of resistant CML.
✅ Improved Patient Outcomes
Offers an effective treatment option for patients with resistant or newly diagnosed CML.
Prolongs progression-free survival and reduces leukemia progression.
✅ Oral Administration
Convenient oral dosing improves patient compliance compared to intravenous treatments.
Summary
Nilotinib丨CAS 641571-10-0 is a targeted anticancer agent primarily used to treat Philadelphia chromosome-positive chronic myeloid leukemia. Its selective inhibition of BCR-ABL kinase offers improved outcomes in resistant cases, making it a cornerstone in modern CML therapy.
